Immunological dysregulation in psoriasis: Pathophysiology, genetic influences, and emerging therapeutic strategies

The persistent, immune-mediated skin condition known as psoriasis affects millions of people globally. This study aims to present a thorough examination of the basic processes that underlie psoriasis, with an emphasis on immunological dysregulation and its consequences for the treatment of the condition. The hallmarks of psoriasis are inflammation, keratinocyte hyperproliferation, and the development of distinct, scaly plaques. The main cause of psoriasis, according to recent developments in immunology, includes both the innate and adaptive immune systems and is considered an aberrant immune response. Cytokines such as TNF-α, IL-17, and IL-23, together with T cells and dendritic cells, are key players in this dysregulation, generating a feedback loop that sustains chronic inflammation in the skin. Apart from pinpointing susceptibility loci such as PSORS1, this review highlights the role of genetic and environmental factors in the pathophysiology of psoriasis. These immunological pathways are the focus of current therapy approaches, and biologics such as TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors have demonstrated exceptional effectiveness in reducing the condition. Ongoing clinical studies are used to examine emerging treatments, such as JAK inhibitors and personalized medicine strategies. According to the review, a better knowledge of immunological dysregulation in psoriasis can result in more personalized treatment plans, which could lessen the disease's burden and enhance patients' quality of life. To create more potent and long-lasting treatment plans, greater study on the immunobiology of psoriasis is essential.